




Università degli Studi del Piemonte Orientale 
“Amedeo Avogadro” 
 
Dipartimento di Scienze del Farmaco 
 
Dottorato di Ricerca in Biotecnologie Farmaceutiche ed 
Alimentari 
XXVI ciclo - a.a. 2010-2013 
 
 
Budget Impact Analyses: 









Università degli Studi del Piemonte Orientale 
“Amedeo Avogadro” 
 
Dipartimento di Scienze del Farmaco 
 








Budget Impact Analyses: 






























To my family 
 
 
Non ti arrendere mai, 
neanche quando la fatica si fa sentire, 
neanche quando il tuo piede inciampa, 
neanche quando i tuoi occhi bruciano, 
neanche quando i tuoi sforzi sono ignorati, 
neanche quando la delusione ti avvilisce, 
neanche quando l’errore ti scoraggia, 
neanche quando il tradimento ti ferisce, 
neanche quando il successo ti abbandona, 
neanche quando l’ingratitudine ti sgomenta, 
neanche quando l’incomprensione ti circonda, 
neanche quando la noia ti atterra, 
neanche quando tutto ha l’aria del niente, 
neanche quando il peso del peccato ti schiaccia… 
Stringi i pugni, sorridi e ricomincia! 
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1.1 The economic evaluation in health care 
In the last decades there has been a growing consciousness on the 
increasing need of health on the one hand and the paucity of resources on the 
other. 
The economic evaluation aims at assessing whereas a new health 
technology provides value for money and, ultimately, if the available budget 
is efficiently allocated, i.e. if we are reaching the maximum level of health 
with the available budget.  
The economic evaluation has been defined as “the comparative analysis of 
alternative courses of actions in terms of both their costs and consequences” 
(1).  
The economic evaluation can help the decision maker to choose among a 
possible wide range of alternatives of resources use (2), paying particular 
attention to the “opportunity cost” which refers to the loss of health benefits 
that would have been created if the resources were used in another course of 
action (3). 
Thus, health economics and economic evaluation can be considered as a 
“link” between economics and healthcare in which the discipline of 
economics is applied to the topic of health (4). 
 






Health technology assessment (HTA) is “a multidisciplinary process that 
summarises information about the medical, social, economic and ethical 
issues related to the use of a health technology in a systematic, transparent, 
unbiased, robust manner. Its aim is to inform the formulation of safe, 
effective, health policies that are patient-focused and seek to achieve the best 
value” (5). 
HTA aims at evaluating new technologies (i.e. drugs, medical devices, 
procedures, settings of care and screening programmes) (6), to determine 
their efficacy, clinical safety, indication for use, economic impact and ethical, 
social and legal implications too (5). 
 





Figure 1: Comparison of alternatives in economic evaluation (3). 
 
Depending on how benefits are measured, economic evaluation can be 
classified as: 
i. Cost Efficacy/Effectiveness Analysis (CEA), should there be an 
important benefit measured in physical units (e.g. life expectancy, 
years of life saved, progression free survival, etc.) (7). 
ii. Cost Utility Analysis (CUA), should the improvement in quality of 
life be an important impact of the treatment; in CUA benefits are 





treatment (ranging from 0 to 1), i.e. QALY (Quality Adjusted Life 
Years saved) (7). 
iii. Cost Benefit Analysis (CBA): in this analysis benefits are 
measured in monetary units (7). 
 
Whereas economic evaluations consider both costs and benefits, Budget 
Impact Analysis (BIA) is carried out to estimate the financial burden for the 
health care payer caused by the adoption and diffusion of a new technology 
(8). 
 
The following sections will briefly describe / analyse the most important 
characteristics of cost effectiveness analysis (CEA), cost utility analysis 
(CUA) and cost benefit analysis (CBA) (table 1). Afterwards, the analysis 
will illustrated the difference between a BIA and an Economic Evaluation. 
 
 
Type of analysis Evaluation of costs Outcomes measure 
CEA Monetary units Physical units  
(years of life saved, progression free survival) 
CUA Monetary units QALY 
CBA Monetary units Monetary units 
 
Table 1: CEA, CUA and CBA 
 
1.2 Cost-Effectiveness Analysis 
In cost-effectiveness analysis (CEA) two different alternatives are 
compared as to their costs and benefits in terms of year of life saved, life 
expectancy, progression free survival etc. This kind of analysis is a complete 
one (1) since it is performed taking into consideration both the costs and the 





It worth mentioning the difference between the term “efficacy” and 
“effectiveness”. The efficacy is the extent at which an intervention fulfils its 
intended effect in a perfect setting of care, while the effectiveness is the 
effect of one intervention in the real world practice. 
The additional cost that one program imposes compared to the additional 
benefit it delivers is expressed by the “Incremental Cost-Effectiveness Ratio” 
(ICER), which is calculated by dividing the incremental cost of the new 
intervention by the incremental change in effectiveness (3). 
 
 
Where: CA is the cost of the new intervention 
  CB is the cost of the comparator 
  EA is the effectiveness of the new intervention 
  EB is the effectiveness of the comparator 
 
The ICER measures incremental costs over incremental benefits (e.g. 
10,000 Euros per Life Years Saved), due to the adoption of the new 
programme. 
The outcome of a CEA (i.e. the ratio between incremental costs and 
incremental benefit), may be represented using the cost effectiveness plane 

















Figure 2: The cost effectiveness plane (3). 
 
If we are either in the quadrant II or in the quadrant IV, one intervention 
“dominates” the other one. Since in the quadrant II the new intervention is 
less costly and more effective, it dominates the other. On the contrary, if it 
falls in the quadrant IV, the new alternative will generally be rejected since it 
would be more costly and less effective (3). 
If the intervention falls in the quadrant I (more effective but more costly), 
or in the quadrant III (less effective but less costly) the ICER should be 
calculated.  
The final decision to adopt or not adopt the new intervention will depends 
on the maximum ICER (threshold) the decision-maker is available to pay, the 
level of priority assigned to the target (disease) and the available resources 
(3). 
Costs included in the analysis depends on the perspective used. The 
perspective may be that of healthcare payer, the single hospital, the patient or 
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Costs may be classified as direct health care costs, other direct costs and 
costs generated by loss of productivity (short-term, long-term or permanent 
absence from work; premature mortality before retirement) (6). 
Evidence on efficacy and effectiveness may derive from single trials / 
observational studies, systematic reviews and meta-analyses (1, 6, 7), and 
experts panel (6). Experts opinion may be collected through the Delphi 
technique (7), where the opinions are gathered through a double-blinded 
“round” series (9).  
 
1.3 Cost Utility Analysis 
The CUA is used when the quality of life is an important outcome, i.e. 
when both morbidity and mortality are affected by the intervention (1, 3, 7). 
The final outcome (i.e. the utility) is generally reported as the cost per 
quality-adjusted life year (QALY) (3) which allows to combine the effects on 
survival and health related quality of life (HRQoL), enabling comparison 
among different areas (10). 
Various methods can be used to measure utility, i.e. a parameter ranging 0 
(death or vegetative status) through 1 (perfect health).  
Direct methods include the time trade-off (TTO) and the standard gamble 
(SG)
 
(3, 6, 10), whereas indirect methods rely on multi-attributes 
questionnaires, like the Health Utilities Index mark 3 (HUI-3), the EuroQol 
five-dimension (EQ-5D), the six-dimensional health State short Form (SF-
6D), derived from the Short Form 36 health survey (3). 
Using a TTO, the interviewee is asked to choose between two alternatives: 
to remain in a certain health status for a determined period of time “t” or to 
be in a perfect health status for a time “x” less then “t”, followed by death 
(fig 3). The amount of years of life the interview is available to give up for a 






Figure 3: Time trade-off (3). 
In the SG technique the interviewee is asked to choose between a 
treatment with an uncertain efficacy but a high number of QALYs and a 
certain treatment with fewer QALYs (6). In the SG the probability to obtain a 
determined outcome are continuously changed until for the patient there is 
not any difference between the two alternatives, i.e. participating in a lottery 
that makes him / she having a higher quality of life (with probability p) and 
probability p-1 to die immediately or remain for a certain number of years in 
the same condition. 
Among the indirect methods the HUI investigates eight health domains, 
with a preference scoring system based on standard gamble utilities measured 
from the general public (11, 12). 
The EQ-5D contains five attributes: mobility, self-care, usual activity, 
pain/ discomfort, and anxiety / depression. Each attribute has three possible 
states which provides 245 possible health states. Utility scores were 
measured for each health state using the TTO technique (13). 
The SF-6D is based on the Short-Form 36 (SF-36) and Short form 12 (SF- 
12) and it consists of six attributes which use data from either 11 items from 
the SF-36 or eight items from the SF-12. Utility values on 249 potential 













Figure 4 illustrates QALYs. Without the intervention, a patient HRQoL 
would deteriorate following the lower curve (grey area), and he would die at 
time death 1. With the intervention the patient’s health would deteriorate 
more slowly, he would live longer, and die at time death 2. The area between 
the two curves measures the number of QALYs gained by the adoption of the 
intervention. This area can be divided into two portions, A and B. The first 
one is represented by the QALYs gained due to a better quality of life and the 
second represents the QALYs gained due to the extension of the quality 
(extension of life) (1, 3). 
 
Figure 4: The QALY (3). 
 
1.4 Decision analytical models 
Economic evaluations compare the expected costs and consequences of 
two alternatives in the long-run or at least since the two alternatives have 
produced the most relevant costs and consequences. Evidences on the long-
run impact of a technology and clinical pathways are generally not available.  
The main objective of a decision analytical modelling is to provide 





evidence (15) and to make explicit the process associated with the decision to 
implement a new intervention in healthcare (16). 
The simplest form of decision model is represented by a decision tree: 




Figure 5: Decision tree 
 
The decision tree starts with a decision node (square) which corresponds 
to the decision point between two (or more) alternative options (3, 17, 18). 
Following the different branches, a chance node (circular symbol) is reached. 
The alternatives following a chance nose are mutually exclusive and the 
probability to occur of all the possible alternatives, which spring from a 
single chance node, should sum exactly to one (17). 
The end points of each pathway are denoted by terminal nodes (triangular 
symbols) with the relevant values or pay-offs, such as costs, life years, or 
QALYs, assigned. By rolling back through the branches of the decision tree it 




























Decision trees are useful for their simplicity and transparency, but they 
lack of any explicit time horizon, making problematic dealing with time 
dependent elements of an economic evaluation. Recursion or looping within 
the decision tree is also not allowed, so that decision-making in chronic 
diseases with recurring events may be not adequately represented by decision 
trees. 
 
The Markov model is more appropriate for these situations (fig. 6). 
Markov models allow for managing more complex processes including many 
variables into the model (17, 18). Such models have been extensively used in 
the evaluation of screening programs (19), diagnostic technologies (20), and 
therapeutic interventions (21).  
Figure 6 illustrates a generic Markov model in which there are three 
different health status A, B, C and death. The arrows indicate that patients 
can move from one status to another or remain into the same health status 
over a discrete period of time (cycles), but they cannot return in a previous 
health status.  
 
 
Figure 6: The Markov Model 
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Despite the Markov model allows to face complexity, it shows diverse 
pitfalls: transition probabilities depend only on the current health status, it is 
not possible to understand where patients come from, and it is not possible to 
determine the time at which the transition take place. These limitations can 
be overcome by introducing temporary states and introducing time 
dependency into transition probabilities (17, 18). 
 
1.5 BIA vs. Economic evaluation  
Economic evaluation provides evidence on the value for money of a new 
technology, but does not give information on its sustainability, i.e. whether 
the available budget is sufficient to cover the expected expenditure, which is 
a crucial information for payers.  
For this reason, economic evaluation has been integrated by BIA. Since 
affordability has become one of the most important priorities, the BIA is 
increasingly required by payers to make a new technology eligible for 
reimbursement and to negotiate its price, both at central and local levels. As a 
consequence, the interest in the BIA of both scientific community and payers 
has increased. 
The BIA compares two scenarios: the scenario with (A) and without (B) 
the new technology. The budget impact is the difference between expected 
spending in Scenario A and Scenario B (8). Whereas economic evaluation 
may use the societal perspective, the BIA is carried out taking the payer’s 
perspective. The budget impact is calculated in the short-term (three to five 
years), whereas cost-effectiveness should incorporate all costs and benefits, 
till they are different between the two interventions under comparison. A 
budget impact is calculated for the whole target population, whereas an 
economic evaluation is performed on an hypothetical cohort population. For 





out to assess the robustness of the results: in CEA a probabilistic sensitivity 
analysis usually integrates one-way analyses. In the BIA a one-way (or two-
way) deterministic sensitivity analysis is preferred. 
 
ITEM CEA BIA 
Purpose Value for money Affordability 
Comparator Comparison between two alternatives Scenario analysis 
Perspective Society Payer 
Time horizon The most appropriate for the disease 
Suggested 3-5 years but can go over 
lifetime 
Data source RCT Real world data 
Population 
Not specified. The analysis is mad for a 
single patient representing the whole 
population with the pathology for which the 




Intervention costs Direct and indirect costs 
Sensitivity analysis Probabilistic One or two way deterministic  
 
Table 2: Comparison between CEA and BIA 
 
1.6 Guidelines for the Budget Impact Analysis 
Both the scientific community, including scientific networks (International 
Society for Pharmacoeconomics and Outcomes Research – ISPOR (8)) and 
individual researchers (Italy 22), and payers (Belgium 23, Canada 24, Ireland 
25, and Poland 26) have recently issued guidelines on BIA. 
All these guidelines investigated the most critical issues in carrying out a 
BIA, including: 
 the perspective used: according to most guidelines the perspective should 
be the one of the budget holder. Only one guideline has suggested to adopt 
a societal viewpoint. The Canadian guidelines states that the drug 
perspective should be adopted, thus providing for a budget silos approach; 
 the scenarios to compare: all guidelines stresses the importance to rely on 





the future scenario as the scenario where either the new treatment does not 
exist or it is not listed and covered by public funds; 
 the population to consider: according to some guidelines, the target 
population should be the population which could generally benefit from 
the intervention; other guidelines explicitly consider the population 
covered by public funds the target of the BIA; 
 the time horizon, which ranges from 1 to 5 years: only one guideline has 
suggested a possible longer time horizon, until the technology reaches a 
steady state; 
 costing and discounting: most guidelines recommends (i) to include all 
relevant resources used (including drugs, patients follow-up, 
complications and adverse events); (ii) to use real world evidence on 
clinical pathway; (iii) to assess unit costs considering the financial flows 
for the payer (hence, not using the notion of opportunity cost). Only few 
guidelines suggest to discount costs, using a 5% rate; 
 sensitivity analysis. This analysis is strongly suggested to validate results, 
demonstrating their robustness. A deterministic sensitivity analysis (DSA) 
is generally considered sufficient, whereas a probabilistic (PSA) one is 
strongly suggested for cost-effectiveness analysis. 
ISPOR (8) 
Perspective The recommended perspective is that of the budget holder. 
Scenarios 
The reference scenario should be the current mix of interventions without the new 
technology. 
The future scenario should be the current mix of interventions with the new 
technology. 
Population 
The population to be included in a BIA should be all patients who might benefit 
from the adoption of the new intervention. 
Time horizon 
Budget impact analyses should be presented for the time horizon of most relevance 
to the budget holder. 
Costing and 
discounting 
The steps in costing are: identifying the resource use that may change, estimating the 
amount of change, and assessing these changes. It is not necessary to discount the 
costs. 
Sensitivity analysis 
Various forms of sensitivity analysis (univariate, multivariate, probabilistic, etc.) 
may be carried out. 
The analyst should compute a range of results that reflect the plausible range of 
circumstances the budget holder will face.  







Perspective Budget holder specifying if national, regional or local. 
Scenarios 
Should start from the current treatment mix in the analysed context (national, 
regional or local) 
Population 
It is necessary to identify the size of the target population to be treated in the 
analysis setting. 
Time horizon Maximum 3 years 
Costing and 
discounting 
All direct medical costs, that may change between the new technology and the 
current mix, should be included.  
Discounting is not necessary. 
Sensitivity analysis Analysis of best and worst case scenario to evaluate the maximum variation range 
 
BELGIUM (23) 
Perspective BIA should be carried out from the healthcare payer’s perspective. 
Scenarios 
The intervention in the BIA is the same as in the economic evaluation, the 
comparator is the usual daily practice without the add-on treatment. 
Population 
The target population should be consistent with the population defined in the 
reimbursement request. 
Time horizon 
The time horizon of the BIA depends on the time needed to reach a steady state. The 




Direct healthcare related costs are included in the reference case.  
It is recommended to calculate both the global budget impact and consequences for 
the different health care payers. 
The Belgian guidelines recommend not to discount costs 
Sensitivity analysis 
One- or multiple-way sensitivity analysis can be performed on the most important 




Public drug plans participating in the Common Drug Review (CDR) process have 
explicitly requested that the analytic framework should be developed from the 
perspective of the drug plan. 
Scenarios 
The reference scenario is a forecasted version of the current market, in which the new 
drug is assumed not to obtain formulary listing. 
The new drug scenario is forecasted in a manner similar to that used for the reference 
scenario; however, in this case, the new drug is assumed to be granted formulary 
listing. 
Population 
The target population comprises individuals who are insured by the public drug plan 
of interest and have the condition of interest.  
All drug plan beneficiaries who are expected to be diagnosed and treated for the 
condition(s) of interest and are eligible to use the new drug be included in the BIA. 
Time horizon A time horizon of 3 years is recommended. 
Costing and 
discounting 
The price of a treatment strategy should be adjusted to consider the mark-ups, 
inventory allowances, business related costs to the pharmacy covered by the drug 
plan, dispensing fees and/or patient co-payments as requested by the drug plan. All 
other premiums and deductibles should be excluded. 
Discounting should not be factored into BIAs because discounted costs do not reflect 
the actual amount that a drug plan can be expected to pay in a given year 
Sensitivity analysis 
Deterministic sensitivity analysis, which includes one-way, multi-way and analysis of 








The BIA should be conducted from the perspective of the publicly-funded health and 
social care system (HSE) in Ireland. 
Scenarios 
The technology should be described in sufficient detail to differentiate it from its 
comparators and to provide context for the study. 
The preferred comparator for the reference case is ‘routine care’, that is, the 
technology or technologies most widely used in clinical practice in Ireland. 
Population 
The target population should be defined based on the approved indication for the 
technology. Stratified analysis of subgroups (that have been ideally identified a 
priori) is appropriate. 
Time horizon 
The core analysis should estimate the annual financial impact over a minimum 
timeframe of five years. 
Costing and 
discounting 
The costs included should be limited to direct costs associated with the technology 
that will accrue to the publicly-funded health and social care system. 
Sensitivity analysis 
Scenario analyses for a range of plausible scenarios and sensitivity analysis must be 
employed to systematically evaluate the level of uncertainty in the budget estimates 




The study perspective should be that of the public purchaser—the key audience for 
such analyses. 
Scenarios NA 
Population The target population for BIA is defined based on the approved indication(s). 
Time horizon 
Ideally, time horizon for the BIA should be until the proposed drug is predicted to 
have achieved a peak or stable market share. 
Annual financial implications to the health-care budget, for drugs as well as total, to 
this time horizon or for at least 2 years after the date of listing on the reimbursement 
list should be estimated. 
Costing and 
discounting 
The approaches to measurement and evaluation of costs vary along a spectrum of 
specificity. 
Micro-costing and gross-costing can be used within a single analysis. 
This analysis should use a 5% discount rate. 
The costs in BIA should be estimated in terms of the payments actually made or the 
savings actually realized by the public purchaser. 
Sensitivity analysis 
The analyst should conduct one-way sensitivity analyses to determine where 
uncertainty or lack of agreement about some key parameter’s value or the functional 
form of the model could have a substantial impact on conclusion. Furthermore the 
analyst should conduct multi-way sensitivity analyses for important parameters. 
 
Table 3: Guidelines on BIA 
 
Despite some agreement on general topics, most guidelines do not discuss 
more specific but important issues, i.e. whether (i) the new intervention is 
expected to raise awareness on the disease, thus increasing the proportion of 
the eligible population actually treated (inducement effect), (ii) off-label use 
of drugs should be included, in the case off-label is currently used, (iii) 





transaction costs should be considered when fee-for-service is used as a 
proxy for unit costs.  
These topics are covered by the ISPOR guidelines that we consider, as other 
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2. The outline of the thesis 
HTA is a discipline aimed at evaluating new technologies (i.e. drugs, 
medical devices, procedures, settings of care and screening programmes), to 
determine their efficacy, safety, indication for use, economic impact and 
ethical, social and legal implications. 
Economic evaluation, as part of the HTA, assesses the benefits and the 
costs of a new health care programme compared with the existing 
alternative(s) for the same disease.  
This comparison provides an indicator – the ICER (Incremental Cost 
Effectiveness Ratio) which measures incremental costs over incremental 
benefit (e.g. 10,000 Euros per Life Years Saved), due to the new programme. 
Depending on how benefits are measured, economic evaluation can be 
classified as:  
(i) Cost Efficacy/Effectiveness Analysis (CEA), should there be an important 
benefit, measured in physical units (e.g. life expectancy, years of life 
saved, progression free survival, etc.);  
(ii) Cost Utility Analysis (CUA), should the improvement in quality of life be 
an important impact of the treatment; in CUA benefits are measured as 
life years saved weighted by the quality of life after treatment (ranging 
from 0 to 1), i.e. QALY (Quality Adjusted Life Years saved); 
(iii) Cost Benefit Analysis (CBA), which measures added benefit in monetary 
units. 
 
Economic evaluation measures value for money of a new technology, but 
does not provide data on its sustainability. The impact on budget of a new 
technology is assessed by the Budget Impact Analysis (BIA). The BIA, 





avoided expenses due to its adoption, may help payers to understand whether 
the new technology is sustainable.  
Economic Evaluation and Budget Impact Analysis have been growing 
their importance in the last years. In fact, they are supporting decision 
making (recommendation to end-users, coverage, price), because resources 
are scarce and should appropriately allocated.  
Since affordability has become one of the most important priorities, the 
BIA is increasingly required by payers to make a new technology eligible for 
reimbursement and in price negotiation, both at central and (possibly) local 
levels. As a consequence, the interest in the BIA of both scientific 
community and payers has increased.  
 
My PhD program has been focused on two topics. 
 
I have firstly analysed the role of economic evaluation and budget impact 
analysis in drugs price and reimbursement in the most important EU 
countries (England, France, Germany, Italy, Scotland, Spain, and Sweden). 
The results of this descriptive analysis have not been published and are 
illustrated in Chapter 4. 
 
The second part of my Phd Program has been focused on BIA. More 
specifically, I have investigated the consistency of published Budget Impact 
Analyses with the relevant ISPOR guidelines, which are widely accepted and 
recognised as the leading ones. The results of this analysis has been 
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Abstract 
Budget impact analyses (BIAs) are playing an increasingly important role 
in health care payers’ decision making. The interest in BIAs is apparent from 
the growing number of published studies and discussions about 
methodological issues. Many guidelines on BIAs have been published to 
date, but the guideline created by the International Society of 
Pharmacoeconomics and Outcomes Research (ISPOR) is the most complete. 
The objective of this paper is to review published BIAs and determine 
whether they are consistent with the ISPOR guideline. 
We carried out a search for BIAs by combining "budget", "impact", and 
"analysis" with the Boolean operator “AND” in Medline, Embase, and Web 
of Science for the period from January 2008 to June 2013. We included only 
original papers. We retrieved 1891 studies, of which 119 were selected for 
the analysis. 
We found that the studies were consistent with some aspects of the ISPOR 
recommendations: the researchers adopted a short time horizon, considered 
relevant costs for the budget holder, and performed a sensitivity analysis. 
However, in many other ways, they did not fully comply with the ISPOR 
guidelines. Few studies were based on an open-population model, many did 




explicitly mentioned that all available treatments were considered. Other 
minor issues (e.g., the inclusion of off-label use of drugs) were never 
mentioned. 
We may conclude that BIAs should be performed with more accuracy, 






Budget constraints and allocative efficiency are major issues in health care 
systems. Health technology assessments (HTAs) have increased in 
importance in the decision-making processes used by regulatory authorities 
and payers (1). HTA covers the full spectrum of health technologies (i.e., 
drugs, medical devices, procedures, settings of care, and screening programs) 
and their impacts (clinical, economic, organisational, ethical, and social 
impact) (2). 
Economics and management contribute to HTAs. They assess value for 
money by performing economic evaluations (3) of health technologies, their 
sustainability (using budget impact analysis, BIA) and their organisational 
impact. 
A BIA compares two scenarios: the scenario with (A) and without (B) the 
new technology / intervention. The budget impact is the difference between 
expected spending in Scenario A and Scenario B (4). BIAs are populated 
with real world data about the target population and the expected additional 
and avoided costs attributable to the new technology. 
 
Because affordability has become one of the most important priorities in 
health care systems, a BIA is increasingly required by payers to make a new 
technology eligible for reimbursement and increasingly used in their price 
negotiations both at central and local levels
 
(5). As a consequence, interest in 
BIAs has increased both in the scientific community and among payers. 
The scientific community, including scientific networks (International 
Society for Pharmacoeconomics and Outcomes Research – ISPOR (4)), 
individual researchers (Italy (8)), and payers (Belgium (6), Canada (7), 




All of the guidelines addressed the most critical issues in BIAs, including 
the following: 
 The perspective used. According to most guidelines, the perspective 
should be that of the budget holder (4, 6, 8, 10). Only one guideline 
suggested adopting a societal viewpoint (9). The Canadian guidelines (7) 
stated that the drug perspective should also be adopted, thus providing for 
a budget silos approach. 
 The scenarios to compare. All of the guidelines stressed the 
importance of relying on real world data to describe the current mix of 
treatments and considering a future scenario where either the new 
treatment does not exist or it is not listed and covered by public funds. 
 The population to consider. According to some guidelines, the target 
population should be the population that could generally benefit from the 
intervention (4, 8-10); other guidelines explicitly consider the population 
covered by public funds as the target of the BIA (6, 7). 
 The time horizon, which ranges from 1 to 5 years. Only one guideline 
suggested using a longer time horizon until the technology reaches a 
steady state (6). 
 Costs and discounts. Most guidelines recommended (i) including all 
relevant resources used (drugs, patient follow-up, complications and 
adverse events); (ii) using real world evidence about the clinical pathway; 
and (iii) assessing unit costs considering the financial flows for the payer 
(i.e., not using the notion of opportunity cost). Only one guideline 
suggested discounting costs, using a 5% rate (10). 
 Sensitivity analyses. A sensitivity analysis is strongly suggested to 
validate the results by demonstrating their robustness. A deterministic 
sensitivity analysis is generally considered sufficient, whereas a 




Although they agree on general topics, most guidelines do not discuss the 
more specific but important issues covered only by the ISPOR guidelines (4), 
i.e. whether (i) the new intervention is expected to raise awareness of the 
disease, thus increasing the proportion of the eligible population actually 
treated (inducement effect), (ii) off-label use of drugs should be included in 
cases where off-label uses are present, (iii) the avoided unit cost should be 
based on fixed or variable unit costs, and (iv) transaction costs should be 





Research question and methods 
This article aims to understand whether the published BIAs are consistent 
with the ISPOR guidelines. A similar analysis was published in 2009 by 
Orlewska and colleagues (5). The authors reviewed “BIAs published to date 
in peer-reviewed bio-medical journals with reference to current best 
practices and discusses where future research needs to be directed”.  
 
We have adopted the following search strategies. Only BIAs were 
investigated. Economic analyses other than BIAs - i.e., cost of illness, cost 
description, cost-outcome description, cost analyses, cost-effectiveness, cost-
utility, cost-benefit - were excluded unless they were performed together with 
a BIA. We included only studies published in English. The period covered 
was January 2008 - June 2013; the previous review on BIA by Orlewska and 
colleague (5) covered the period of time between January 2000 and 
November 2008. Original papers were included; conference papers, abstracts, 
case reports, letters, comments, editorials, and review papers were excluded. 
The PubMed / Medline, Embase, and Web of Science databases were used. 
The search terms were "budget", "impact", "analysis", and "model". The 
terms were combined using the Boolean operator “AND”. Following 
Cochrane recommendations, the “NOT” Boolean operator was not used. We 
did not carry out any assessment of methodological quality because of the 
absence of standards for quality assessment of BIAs and the descriptive 
nature of the article.  
 











Which perspective is adopted in the study? 
Which cost categories have been included? 
Scenarios to compare 
Are the two scenarios well specified? 
Does the reference scenario include all the available treatment 
alternatives? 
Are market shares illustrated? 
Do the scenarios include off-label drug use? 
a
 
Are the assumptions about the current and future scenarios 
identified and justified? 
Population & 
subgroups 
Does the analysis include all of the patients who are expected to 
be eligible from the perspective of the payers? 
Does the study consider an open population (i.e., individuals 
enter or leave the population depending on whether they currently 
meet the analyst's criteria for inclusion) or is it a cohort-based 
analysis? 
Does the analytical framework allow for subgroups to be 
considered?  




What is the time horizon used for the analysis? 




consumption and unit 
costs 
What information source is used for resource consumption? 
How are the unit costs for health services estimated? 
Are fixed costs considered in the long run?
 a
 
Are transaction costs included?
 a
 




Is a sensitivity analysis carried out? 
Which sensitivity analyses have been carried out? 
Discounting 
Is any discounting applied to the costs? 
What discounting rate is used? 
a
 These items, which are included in the ISPOR guidelines, will not be discussed in the 






Using the above-mentioned criteria, 1891 articles were retrieved. A total 
of 1753 articles were excluded after reviewing the title and the abstract: 976 
because they were focused on sectors other than health care (e.g., the 
environment); 777 discussed the role of BIA in decision-making, they only 
mentioned the budget impact issue within a cost-effectiveness (CEA) or cost-
utility (CUA) analysis, or they were not published in English. The remaining 
138 articles were fully read, and 19 were excluded because they were not 
BIAs despite the information included in the title and the abstract. Hence, 
119 articles (11-129) were analysed (Figure 1). 
 




The selected BIAs were carried out in the US
 
(34 studies), the UK
 
and 
Spain (15 studies each), France and Italy
 
(9 studies each), Canada (7 studies), 
Germany (6 studies), Belgium (4 studies), Japan and Thailand
 
(3 studies 




studies each), Ireland, Greece, Switzerland, Finland, Portugal, Czech 
Republic, New Zealand, South Africa, Brazil, Colombia and India (1 study 
each). We also found five multi-country studies (33, 56, 109, 116, 117). 
 
The diseases covered included cancer (24 out of 119) and chronic diseases 
(23 out of 119). The other areas of interest were cardiovascular diseases (14 
out of 119), viral infections (13 out of 119), central nervous system disorders 
(10 out of 119), bacterial infections (6 out of 119), gastrointestinal diseases (5 
out of 119), and rare diseases (4 s out of 119). Most BIAs addressed drugs or 
vaccines (92 out of 119). A minority considered the impact of prevention or 
screening programs on health care budgets (18 out of 119), and in nine 
studies a BIA was carried out for a device or a surgical procedure. 
 
Although the ISPOR guidelines suggest considering the population under 
treatment (i.e., individuals entering or leaving the treatment group depending 
on whether they meet the analyst’s criteria for inclusion), most of the 
retrieved BIAs relied on a cohort-based population. Of the studies, 13% 
adopted an open-population approach, 50% (most of them integrated with an 
economic evaluation analysis) adopted a virtual cohort population (e.g., 
1,000 patients), and 37% adopted a fixed cohort-based population estimated 
using prevalence data. It is worth mentioning that seven studies also 
performed analyses for subgroups (32, 44, 58, 61, 68, 101, 113). 
The ISPOR guidelines state
 
that BIAs should adopt the perspective of the 
budget holder, who should be identified as a national, regional or local payer. 
Sixty-three studies adopted the national health care payer perspective (i.e., a 
national health service / system, a national social insurance system, or 
Medicare for the US), thirty-eight assumed the local health care payer 




insurance, or managed care organisations for the US), one study adopted both 
a national and local health payer perspective, six studies adopted a societal 
perspective, seven adopted both the societal and the health care perspective 
and four studies did not specify a perspective (Table 2). 
All of the selected studies included direct health care costs (Table 2). Drug 
costs were always included, except in one study that focused on prevention. 
Twenty-two studies included drug costs exclusively, thirty-nine studies 
included the cost of treatment and also the cost of drugs used to treat adverse 
events and twenty-six studies that focused on injectable drugs considered 
administrative costs. More than 50% of BIAs incorporated the patients’ 
clinical pathway, thus estimating the (avoided or incremental) costs of 
inpatient services (51% of studies) and outpatient services (42% of studies). 
 





Direct costs considered 
Number of 
studies 
National health care payer  63 





Local health care payer 38 Inpatient services 60 
Society 6 Outpatient services 49 
National and local health care 
payer  
1 
Adverse events 39 
National health care payer and 
society 
6 
Local health care payer and 
society 
1 
Drugs administration costs 26 
 
Not available  4 
a One study [74] focused on a prevention program and only outpatient services were included. 
 
 
Most of the BIAs did not include all available options in the analyses of 




available, and the majority of these studies (71 studies) gave an explicit 
rationale for this choice. In 21 studies, the authors considered all available 
treatments in the reference scenario. In 23 BIAs, although it was not 
explicitly declared by the authors, we assumed that all available treatments 
options were considered. In 1 study (110) the data were not available (Figure 
2). 
 





In 29 studies, the market share changes over time, reflecting the gradual 
market uptake of the new therapy, whereas in 16 studies the market share is 
fixed over time. In the remaining 73 studies, the market shares for the 
interventions considered by the author were not mentioned. One study (81) 
illustrated the budget impact with both fixed and variable market shares. 
 
The time horizon in the selected studies ranged from 1 year to lifetime 




using the time horizon that has the most relevance to the budget holder; other 
guidelines explicitly state that the time horizon should range from 3 to 5 
years. Thus, in our analysis, the studies adopted an appropriate time horizon: 
in more than 80% of the studies, it was less than 5 years. 
 




Most of the studies used multiple data sources to determine resource 
consumption. The existing literature was the most common source (75 
studies relied on data from the literature), and 39 studies relied on an expert 
panel, which is considered the weakest information source. Many studies (47 
out of 119) used primary information, including clinical records, insurance 
claims and other administrative databases. The unit costs for inpatient and 
outpatient services were estimated from fee-for-service information (46% of 
studies), the literature (33%), primary data (18%) and expert opinion (5%). In 
most studies, the costs were not discounted, which is consistent with the 
ISPOR guidelines. An average 3% discount was applied in 21 studies, most 




A sensitivity analysis was carried out in 80% of the studies. Consistent 
with the ISPOR guidelines, most of the sensitivity analyses are deterministic 
(72 out of 119 studies), showing the robustness of the results to variations in 
one or two parameters, or they were scenario-based (17 studies). In a few 
studies (29 out of the 119 retrieved publications), a probabilistic approach 




Discussion and conclusion 
Despite the growing interest in sustainability, the number of BIAs 
published in peer-reviewed publications is still limited, according to our 
review. This result may be explained by the following circumstances: (i) 
economic evaluations are more interesting for the scientific community, and 
BIAs are more interesting for the payers; (ii) many BIAs are presented as 
posters at conferences and may not be published as articles; (iii) BIAs are 
mostly published at the national level; and (iv) allocative efficiency has been 
considered more important than affordability by the scientific community. 
 
Previous reviews (5) have shown that BIAs follow some major aspects of 
the guidelines, including the perspective adopted, the categories of costs 
included, the interventions considered in the two scenarios and the data 
sources used. For a few topics (i.e., the population and time horizon), the 
consistency between the studies and the guidelines was lower. We found 
similar results for (i) the perspective used, which was that of the budget 
holder, with a few exceptions represented by some studies that adopted a 
societal perspective, and (ii) the population, with many studies relying on a 
cohort-based approach and only seven studies performing subgroup analyses 
(32, 44, 58, 61, 68, 101, 113). With regard to other crucial issues, our results 
are different from the results of the previous review. As for cost categories, 
only half of the studies included all health care services, whereas many of 
them focused on drug costs. With regard to market share, ISPOR 
recommends considering the actual market share of each intervention as the 
starting point for future scenarios and taking into consideration that the 
market penetration rate of the new intervention could be gradual over time. In 
62% of the studies, market share was not considered. On the contrary, 




guidelines in terms of the time horizons used, our review found that the time 
horizon was less than 5 years in most of the studies retrieved.  
Our analysis also found that the methodological requirements were 
partially met by the reviewed studies. For example, the BIAs mostly relied on 
the literature to design and populate the clinical pathways in BI models 
(primary information was only used in 39% of the studies) and on fee-for-
service information to estimate the unit costs for inpatient and outpatient 
services. 
 
It is also worth mentioning that some minor aspects addressed by the 
ISPOR guidelines have been completely disregarded by the published 
studies. No studies reported the off-label use of drugs in the current treatment 
mix or considered the hypothesis that the new intervention might raise 
awareness of the disease, thus increasing the proportion of the eligible 
population that is actually treated. The extension of the time horizon was 
never justified because a steady state is reached after five years, as one 
guideline suggested, but it would have been justified on the grounds of the 
chronic nature of certain diseases (HIV (22, 40), diabetes complications 
(126), Alzheimer’s disease (108),
 
chronic pain (117)). Transaction costs, 
which may be considered when fee-for-service is used as a proxy for unit 
costs, were never investigated. Although the ISPOR guidelines suggest 
considering the fixed costs only in the long run, most of studies did not 
distinguish between fixed and variable costs and of those that did (11, 13, 15, 
20, 38, 43, 54, 62, 85, 107, 114, 126) only one study (38) had a time horizon 
of 10 years. Finally, rebates on the cost of drugs were rarely considered, even 





Our review has one main limitation. We included many studies in which a 
BIA was integrated with a CEA or a CUA rather than being carried out alone. 
This may imply that the CEA / CUA drove some of the methodological 
choices for the BIA, e.g., (i) the consideration of a single therapy / 
technology (as for the CEA) rather than all current therapies and (ii) the use 
of a cohort-based population.  
 
Despite this limitation, this review indicated that further steps should be 
taken to improve the rigour of BIAs, thus increasing their usefulness for 
payers’ decision-making processes. For this reason the new Task Force 
created at ISPOR, which aims at updating the previous principles of good 
practice, may represent an important further step towards a more rigorous 
application of the BIA methodology (130). 
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Value for money and sustainability have become crucial for payers in their 
decision-making process. 
In this work I have investigated the role of cost effectiveness analysis 
(CEA) and budget impact analysis (BIA), in pharmaceutical pricing and 
reimbursement policies across the five major European countries (France, 
Germany, Italy, Spain, and UK) and Sweden. 
In addition, I have investigated the consistency among decisions taken by 
the HTA Agencies: the analysis has been focused on the French 
(Transparency Commission) and the Scottish (Scottish Medicine 
Consortium) appraisal for drugs which have not been recommended by the 
National Institute for Health and Care Excellence. 
Finally, the evidence on the impact of P&R procedures on market access 






The process which takes place before a new drug is introduced into the 
market is long, risky and complex. 
This process is illustrated by the Figure 1 (1) and starts with the pre-
discovery phase in which researchers focus on the unmet medical need of a 
disease and identify and validate a new target. After that, trough different 
processes (nature, de-novo, high-throughput screening and biotechnology), a 
new promising molecule (lead compound), that could become a new drug, is 
identified. The discovery phase usually terminates with the pre-clinical 
laboratory and animal testing during which the safety of the new compound 
is investigated and assessed. 
The development phase is composed by three different steps: phase I, II, 
III, in which the new drug is tested on a small group of healthy volunteers, on 










































































Time 3 – 6 years 6 – 7 years 






Only one out of 5000 / 10000 compounds reaches the market, after a 
period of time of nearly 15 years (2). 
In Phase IV safety profile in real-world and effectiveness are investigated.  
Once the pre-marketing phase has been completed, the new drug is 
assessed to get marketing approval. In the European Union (EU) the 
centralized procedure (3) is mandatory for human medicines for the treatment 
of HIV/AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune 
and other immune dysfunctions, and viral diseases; medicines derived from 
biotechnology processes; advanced-therapy medicines; and orphan 
medicines. For other drugs which are intended to be marketed in more than 
one EU countries, the relevant company may apply for a decentralised 
procedure or mutual recognition (3). 
Marketing approval makes the product marketable. Further steps are 
needed to get reimbursement and price. These steps are usually referred as 
the fourth hurdle for market access, because, besides efficacy, safety (and 
quality in the production process), economic impact is usually considered (4, 
5). More specifically, the role of economic evaluation and budget impact in 







My research has been focused on three aspects. 
Firstly, I have investigated the assessment and appraisal processes of new 
drugs for reimbursement and price. The analysis involved the following 
agencies: HAS (Haute Autorité the Santé (6)) for France, IQWIG (Institute 
for Quality and Efficiency in Health Care (7)) for Germany, AIFA (Italian 
Medicine Agency (8)) for Italy, ISCIII (Instituto de Salud Carlos III (9)) for 
Spain, NICE (National Institute for Health and Care Excellence (10)) and 
SMC (Scottish Medicines Consortium (11)) for England and Scotland 
respectively (UK) and SBU (Swedish Council on Health Technology 
Assessment (12)) for Sweden. 
Secondly, I have scrutinised differences across the assessments/appraisals, 
comparing NICE, HAS and SMC. 
The last topic investigated was the impact of the price and reimbursement 
on the market access delays. The whole process does not take place 
simultaneously in different countries and the time required for each agency to 







The HTA agencies decision-making process 
The decision-making process of the main HTA agencies in Europe and 
requirements for price and reimbursement process are illustrated in Table 1. 
In England there is the most important HTA agency in Europe, named 
NICE (National Institute for Health and Care Excellence). Technical 
assessment and appraisals (recommendations bases upon assessment) are 
carried out following an early identification of new products, through horizon 
scanning and referred by Ministers, following advice from an expert panels 
(13). Recommendations for the NHS usually take into consideration the 
clinical evidence and the incremental cost effectiveness ratio (ICER) where 
the benefits are measured through the quality adjusted life-years (QALY) 
gained. Generally NICE recommends an intervention with an ICER under 
£30,000 per QALY (14). The relevant documentation (Single or Multiple 
Technology Appraisal - STA/MTA) is fully available (15). These appraisals 
are often used by other European HTA organisations to perform their own 
assessments. 
In Scotland, the Scottish Medicines Consortium (SMC) informs the 
Regional Health Board and the related Area Drugs and Therapeutic 
Committee (ADTC) on clinical evidence and cost-effectiveness of new drugs, 
like the NICE does. However, in Scotland there is not any official threshold 
for the ICER (16). To get a positive recommendation pharmaceutical 
companies are requiring to complete a New Product Assessment form, which 
includes the following sections: registration details, alternative treatments, 
efficacy, comparative safety, clinical effectiveness, economic evaluation, 
resource implications (budget impact). Like in England, the SMC may take 
the decision to recommend, not recommend or recommend with restrictions 




In France, the assessment of new drugs is performed by the French 
National Authority for Health (Haute Autorité de Santé – HAS). More 
specifically, the assessment is carried out by the Transparency Commission 
(TC). This assessment is focused on clinical evidence (18). The absolute 
benefit is firstly (SMR - Service Médical Rendu) evaluated looking at the 
disease severity, the efficacy and the impact on public health. This 
assessment is used by the social insurance system to decide whether the new 
products should be covered by the Social Insurance System and level of co-
payment. Secondly, the TC performs a comparative assessment to identify 
the added value (ASMR - Amélioration du Service Médical Rendu). This can 
lead to an ASMR level I (Major), II (Important), III (Moderate), IV (Minor) 
or V (None). ASMR is a parameter used in price negotiation carried out by 
the Economic Committee (19, 20). 
In Germany there are several actors which play a role in the HTA process; 
among those the most important are: the Federal Joint Committee (G-BA), 
the Institute for Quality and Efficiency in Health Care (IQWiG), the German 
Institute for Medical Documentation and Information (DIMDI) and the 
statutory health insurance (SHI). The IQWiG, on the behalf of G-BA and 
Ministry of Health (MoH), is responsible for the assessment of new 
pharmaceutical products, but its evaluation is not mandatory for the final 
decision, which is taken by the G-BA. The DIMDI collects information about 
new intervention and the DAHTA@DIMDI performs HTA to support health 
policy, but not to determine the benefit package, i.e. the list of reimbursable 
drugs (21). 
In Italy a central role is played by the Italian Medicine Agency (AIFA). 
AIFA, through two committees (CTS – Scientific Committee; CPR – Price-
Reimbursement Committee) assesses new drugs according to the clinical 




innovative’ products and orphan drugs, but CEA has been usually 
disregarded, because of the existence of a drug budget (23). 
In Spain the NHS is composed by the Ministry of Health and the Regional 
Health Departments both coordinated by the National Health System 
Interterritorial Council. The latter one is responsible for providing the benefit 
package for the whole population. Drugs, medical technologies and 
procedures are assessed through both at the central level by the Instituto de 
Salud Carlos III (ISCIII) and at the local level by the regional HTA agencies. 
The HTA process is aimed at assessing costs, efficiency, effectiveness, safety 
and health care utility of a new intervention for its introduction into the 
benefit package, as well as the exclusion of those already provided (24, 25). 
In Sweden the NHS together with the 18 Country Councils, which are 
present in the respective regions, provides healthcare to the whole population. 
On the territory there are several organisations which cooperate in the 
assessment of new interventions, but the most important are the Swedish 
Council on Health Technology Assessment (SBU) and the Dental and 
Pharmaceutical Benefits Board (TLV). SBU performs a complete HTA and 
gives recommendations to TLV which requires a CEA with a societal 
perspective and an estimate of the total impact on burden of disease using 
quality adjusted life years (QALYs) as measure of outcomes (26, 27). 
Table 1 summarizes for each country the criteria used to assess a new 










Drugs prices and reimbursement in Europe 
 
United Kingdom. Prices are freely determined by the pharmaceutical 
companies, after the marketing authorisation has been granted. Since drugs 
prices do influence cost-utility ratio, a too high price will make the cost-
effectiveness overcoming the threshold. Besides threshold on cost-
effectiveness, prices are indirectly regulated through the PPRS 
(Pharmaceutical Price Regulation Scheme). A more explicit value-based 
pricing is going to be introduced in 2014. In the United Kingdom 
reimbursement is not influenced by the assessment: any drugs is 
automatically reimbursable unless it is put on the ‘national negative list’. 
Reimbursement is mostly decided relying on efficacy/effectiveness, safety, 
severity of disease, cost-effectiveness, value for money and ease of use for 
patients (29). 
France. Prices are set by the Economic Committee for Health Products 
considering, among others aspects, the ASMR level. Products with an 
insufficient SMR level do not receive reimbursement. The level of 
reimbursement and co-payment is decided by the National Insurance (20). 
Germany. Prices are freely set by the companies, but subject to (a) a 
therapeutic reference pricing, should they are not innovative, in comparison 
with the existing alternatives and (b) according to the jurisdiction introduced 
in 2011, to a rebate should they are covered by the social insurance system 
and consistently with their added value. (30). 
Italy. Price and reimbursement are both and simultaneously negotiated by 
AIFA. In Italy a positive and a negative lists co-exist: in the first one 
medicines reimbursed by the National Health Service are listed, in the second 
pharmaceuticals such as non-prescription or life-style pharmaceuticals are not 




Spain. After marketing authorisation, both pricing and reimbursement are 
managed by the Directorate of Pharmaceutical and Healthcare Products 
(DGFPS). The inclusion in the national reimbursement list is mandatory 
throughout the country, but many regions (Comunidades Autonomas) have 
their own independent HTA agency, which may decide additional hurdles to 
market access for drugs (31). 
Sweden. Price negotiation and reimbursement for drugs are both managed 
by TLV: prices are freely set by the manufacturer but, since the proposed 
price is an element in the assessment of the cost-utility ratio, a too high price 
will make the cost-efficacy of a medicine unacceptable. The reimbursement 
process takes into account the cost-effectiveness assessment as well as the 
principles of human value, need and solidarity. Reimbursement levels are 
progressive (from 0% to 100%), depending on previous consumptions (32). 
 
Appraisal: which differences across agencies? 
Assessment/appraisals across countries have been compared if publicly 
available. England, France and Scotland were the unique countries were 
complete appraisals were published on the website of the relevant HTA 
agency (33-35) (table 2). At present, also the appraisal / assessment by G-BA 
and IQWIG, within the new P&R process, are published. 
. NICE appraisals were firstly investigated: in October 2011 31 drugs were 
not recommended, 68 were recommended for particular use and 65 
recommended, out of 165 Single Technology Appraisal (STA). Negative 
appraisal are mostly motivated by a high cost/effectiveness ratio (over 
acceptable threshold), an insufficient clinical evidence  anthe circumstance 





Negative recommendations by NICE seem to be consistent with the 
assessment of the two other agencies investigated. The ASMR score in 
France were very low for drugs non recommended by NICE  
The Scottish Medicine Consortium has accepted 2 of the 31 drugs not 
recommended by NICE and 7 drugs were accepted for restricted use, whereas 
15 pharmaceuticals were not recommended for use within the Scottish NHS. 
 
 




Price and reimbursement: which impact on market access delays 
An evaluation of market access delays has been carried out by the 
European Federation of Pharmaceutical Industries and Associations (EFPIA), 
with the collaboration of IMS Health. For such a purpose, the Patient Waiting 
to Access Innovative Therapies (W.A.I.T.) indicator has been developed (36). 
The W.A.I.T. indicator shows the rate of availability of medicines and the 
average time between marketing authorisation and patient access (i.e.. 
completion of post-marketing authorisation, including pricing and 
reimbursement processes). 
Figure 1 shows W.A.I.T. indicators for major EU countries and Sweden. 
UK and Germany have in principle an immediate market access, because 
they have not any positive list. However, as I mentioned before, in UK 
recommendations by NICE are binding: if a drug is not recommended, it 
cannot be used at the expense of the NHS.  
 For other countries delay between marketing approval and marketing 
authorisation ranges from 206 days for Sweden to 349 days in Spain. 
 
Figure 1: Days between market access and availability of a new drug and 







Economic evaluation (CEA) and Budget Impact Analysis are becoming an 
important component of drugs price / reimbursement negotiation.  
This is particularly true for the CEA. Our analysis on the most important 
European Countries (France, Italy, Germany, Spain and the UK) and Sweden, 
has shown that CEA is explicitly used by most of them. The budget impact is 
not explicitly mentioned in some countries, even if it is actually used to 
understand the sustainability in all countries investigated.  
The methodological framework for comparative efficacy / effectiveness 
and economic evaluations is very complete: there are many guidelines, which 
have been developed by scientific societies, networks of HTA agencies, and 
single countries. The circumstance that this common general framework is 
demonstrated by a high level of consistency among clinical assessments (and 
innovativeness ranking). 
Several national guidelines have been published also for budget impact 
studies. The most complete is represented by the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) [see Chapter 3]. 
However, there are still huge variations in the perspectives used in budget 
impact analysis provided to the HTA Agencies. In some countries (e.g. the 
UK), a health care budget impact analysis may be used. In other countries, 
where “silos budgeting” prevails (such as in Italy), the budget impact is 
required for drugs. 
Hence, despite a general trend towards a higher consensus over 
comparative effectiveness and economic evaluation, there is a high 
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In the last years there has been a huge increase in the interest in Economic 
Evaluation and Budget Impact Analysis (BIA) by the scientific community 
and the payers. This interest is motivated by an increasing pressure of budget 
constraints and the opportunity to understand the value for money of a new 
technology and the existing ones.  
The role of economic evaluation in decision making is very different 
across countries. In some countries (England, Scotland, Sweden among 
countries I have investigated, together with Australia and The Netherlands) 
cost-efficacy (cost-utility) plays an important role, whereas in other countries 
economic evaluation is either disregarded or does not play a crucial role.  
On the contrary, in all countries budget impact is explicitly or implicitly 
used by payers, both at national and regional levels (if any). 
 
This interest in the BIA is witnessed by a growing number of guidelines 
and publications on this topic. One of the most complete guidelines has been 
published in 2007 by ISPOR. These guidelines have been recently updated, 
but the final version of the new guideline is not available so far.  
 
Despite this growing interest, the number of BIAs published in peer-
reviewed articles is still limited, according to our review. The limited number 
of published results may be motivated by the perception that the discipline is 
not sufficiently mature and methodologically supported. Another reason is 
that economic theory shows greater interest in allocative efficiency than in 
budget-impact analysis.  
Our analysis covers all BIAs retrieved from the literature and published 





than 5 years), costing (resource consumption and unit costs), sensitivity 
analysis (performed nearly in every study considered) and discounting 
(generally not applied). As for scenarios to compare, market shares and 
eligible population, published studies are less consistent with guidelines. 
Generally speaking, it seems that BIAs are not structured as they should be to 
influence decision-maker, together with other indicators. 
 
Despite the limitations of published studies, we expect a further increase 
in the interest in Budget Impact Analysis in the future. This growing interest 
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This section illustrates the checklist (extraction template) for budget 
impact analyses and the whole database  
 


















































































































ADTC Area Drugs and Therapeutic Committee 
AIFA Italian Medicine Agency 
ASMR Amélioration du Service Médical Rendu 
BIA  Budget Impact Analysis 
CBA Cost Benefit Analysis 
CEA Cost Effectiveness Analysis 
CEP Cost Effectiveness Plane 
CHMP Committee for Medicinal Products for Human Use 
CTS Scientific Technical Committee 
CUA Cost Utility Analysis 
DAHTA German Agency for Health Technology Assessment 
DGFPS Directorate of Pharmaceutical and Healthcare Products 
DIMDI German Institute for Medical Documentation and 
Information 
DSA Deterministic Sensitivity Analysi 
EFPIA European Federation of Pharmaceutical Industries and 
Associations 
EMA European Medicines Agency 
EQ-5D Euro Quality of Life 5 Dimensions 
G-BA Federqal Joint Committee 
HAS Haute Autorité de Santé 
HRQoL Health Related Quality of Life 
HTA Health Technology Assessment 
HUI-3 Health Utilities Index Mark 3 
ICER Incremental Cost Effectiveness Ratio 




ISCIII Institudo de Salud Carlos III 
ISPOR International Society for Pharmacoeconomics and 
Outcomes Research 
LEA livelli essenziali di assistenza 
MoH Ministry of Health 
MTA Multiple Technology Appraisal 
NHS National Health Service 
NICE National Institute for Health and Clinical Excellence 
NMB Net Monetary Benefit 
PPRS Pharmaceutical Price Regulation Scheme 
PSA Probabilistic Sensitivity Analysis 
QALY Quality Adjusted Life Years saved 
QoL Quality of Life 
RCT Randomised Controlled Trial 
SBU Swedish Council on Health Technology Assessment 
SF-6D Short-form 6 Dimensions 
SG Standard Gamble 
SHI Statutory Health Insurance 
SMC Scottish Medicines Consorium 
SMR Service Médical Rendu 
STA Single Technology Appraisal 
TC Transparency Commission 
TLV Dental and Pharmaceutical Benefit Board 
TTO Time Trade-Off 
W.A.I.T. Patient Waititng to Access Innovative Therapies 
Indicator 
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